

March 23, 2021

**Olympus completes transfer of its regenerative medicine business
Olympus RMS to Rohto Pharmaceutical**

Tokyo, March 23, 2021— Olympus Corporation (“Olympus” – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) today announced the completion of the transfer of its subsidiary, Olympus RMS Corporation (“Olympus RMS”- President and Representative Director: Masahiko Hamano), which specializes in manufacturing and development of regenerative medicines, to Rohto Pharmaceutical Co., Ltd. (“Rohto”- President and Chief Operating Officer: Masashi Sugimoto).

The decision to transfer the entire stakes of Olympus RMS to Rohto Pharmaceutical comes after Olympus’ comprehensive review on how to further accelerate the R&D and operations of its regenerative medicine business. Rohto was identified as the best owner as it has strong therapeutic focus on regenerative medicine business.

Olympus RMS will continue to operate as a leading regenerative medicine technology company as part of Rohto Pharmaceutical, engaged in manufacturing and marketing of pharmaceuticals and cosmetics products. Olympus RMS is currently focusing on the development of autologous cultured chondrocytes, known as cartilage cells. The therapy is intended to reproduce and proliferate cells in a laboratory and then implants them back into the damaged joint.

The transfer of Olympus RMS is a part of Olympus’s broader corporate strategy to enhance and establish its position as a leading global medtech company, which was introduced in November 2019. Olympus will continue to focus on maintaining its leadership in endoscopy through expanding both Endoscopic Solution and Therapeutic Solutions Divisions.

As part of the transaction, Olympus will transfer 100% of the outstanding shares of Olympus RMS to Rohto, immediately after acquiring shares of Olympus RMS owned by the joint venture partner, Sewon Cellontech.

Olympus strives to become a leading global medtech company. That means transforming itself into an organization with more resilience and agility for sustainable growth. Olympus will continue to offer technologies and solutions for making people’s lives healthier, safer and more fulfilling.

Olympus RMS facts:

Company name:	Olympus RMS Corporation
Headquarters:	4F NTB Hachioji Building, 3-1-7 Myojin-cho, Hachioji, Tokyo

President & Representative Director: Masahiko Hamano

Business outline:

- R&D on cultured chondrocyte implantation therapy
- Innovations pertaining to the regenerative medicine and assessment

Number of employees: 37 (as of March 1, 2021, including contractors and temporary staff)

Date of establishment: December 2008
Joint venture between Olympus Corp. and Sewon Cellontech Corp.

Capital: 10 million JPY

All company and product names that are mentioned in this news release are registered trademarks of respective companies.